Stimulation of the rat subthalamic nucleus is neuroprotective following significant nigral dopamine neuron loss
| Autor: | Timothy J. Collier, Katrina L. Paumier, Brian T. Terpstra, Kathy Steece-Collier, Anne L. Spieles-Engemann, Lalitha Madhavan, Michael M. Behbehani, Sara E. Gombash, Brian F. Daley, George T. Mandybur, Caryl E. Sortwell, S.L. Wohlgenant, Jack W. Lipton |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2010 |
| Předmět: |
Male
Parkinson's disease Deep brain stimulation medicine.medical_treatment Dopamine Stereology Stimulation Substantia nigra 6-hydroxydopamine Neuroprotection Subthalamic nucleus Article lcsh:RC321-571 Rats Sprague-Dawley Parkinsonian Disorders Medicine Animals lcsh:Neurosciences. Biological psychiatry. Neuropsychiatry Cell Death business.industry Neural Inhibition medicine.disease Symptomatic relief Rats nervous system diseases Substantia Nigra Disease Models Animal Treatment Outcome surgical procedures operative Neurology nervous system Cytoprotection Nerve Degeneration business Neuroscience therapeutics medicine.drug |
| Zdroj: | Neurobiology of Disease, Vol 39, Iss 1, Pp 105-115 (2010) |
| Popis: | Deep brain stimulation of the subthalamic nucleus (STN-DBS) is efficacious in treating the motor symptoms of Parkinson’s disease (PD). However, the impact of STN-DBS on the progression of PD is unknown. Previous preclinical studies have demonstrated that STN-DBS can attenuate the degeneration of a relatively intact nigrostriatal system from dopamine (DA)-depleting neurotoxins. The present study examined whether STN-DBS can provide neuroprotection in the face of prior significant nigral DA neuron loss similar to PD patients at the time of diagnosis. STN-DBS between two and four weeks after intrastriatal 6-hydroxydopamine (6-OHDA) provided significant sparing of DA neurons in the SN of rats. This effect was not due to inadvertent lesioning of the STN and was dependent upon proper electrode placement. Since STN-DBS appears to have significant neuroprotective properties, initiation of STN-DBS earlier in the course of PD may provide added neuroprotective benefits in addition to its ability to provide symptomatic relief. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|